Bruton's tyrosine kinase inhibitors (BTKi) have prolonged survival in chronic lymphocytic leukemia (CLL), however continuous administration increases toxicity.
Little is known about clinical outcomes of patients who discontinue BTKi for reasons other than CLL progression.
We aimed to report these outcomes.
